Morgan E (2017) Regulation of drug-metabolizing enzymes and drug metabolism by inflammatory responses. In: Xie W (Ed.). Drug metabolism in diseasesed. Academic Press

Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR (2018) Disease-Associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a white paper from the international transporter consortium. Clin Pharmacol Ther 104(5):900–915. https://doi.org/10.1002/cpt.1115

Article  PubMed  Google Scholar 

Liu L, Evers R, Montgomery D (2020) Protein drug-drug interactions for therapeutic proteins. In: Ma S, Chowdhury, SK (Ed.) Identification and quantification of drugs, metabolites, drug metabolizing enzymes, and transporters ed. Elsevier, pp 387-416

Coutant DE, Boulton DW, Dahal UP, Deslandes A, Grimaldi C, Pereira JNS, Säll C, Sarvaiya H, Schiller H, Tai G, Umehara K, Yuan Y, Dallas S (2023) Therapeutic protein drug interactions: a white paper from the international consortium for innovation and quality in pharmaceutical development. Clin Pharmacol Ther 113(6):1185–1198. https://doi.org/10.1002/cpt.2814

Article  CAS  PubMed  Google Scholar 

Morgan E (2017) Regulation of drug-metabolizing enzymes and drug metabolism by inflammatory responses. In: Xie W (ed) Drug metabolism in diseasesed. Academic Press, pp 21–58

Chapter  Google Scholar 

Naito T, Tashiro M, Yamamoto K, Ohnishi K, Kagawa Y, Kawakami J (2012) Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Eur J Clin Pharmacol 68(10):1411–1418. https://doi.org/10.1007/s00228-012-1266-x

Article  CAS  PubMed  Google Scholar 

Xu Y, Hijazi Y, Wolf A, Wu B, Sun YN, Zhu M (2015) Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity. CPT Pharmacometrics Syst Pharmacol 4(9):507–515. https://doi.org/10.1002/psp4.12003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, Pitou C, Hall SD (2015) Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window. Clin Pharmacol Ther 98(1):76–86. https://doi.org/10.1002/cpt.128

Article  CAS  PubMed  Google Scholar 

Einolf HJ, Zhou J, Won C, Wang L, Rebello S (2017) A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of Sonidegib (LDE225) with perpetrators of CYP3A in cancer patients. Drug Metab Dispos 45(4):361–374. https://doi.org/10.1124/dmd.116.073585

Article  CAS  PubMed  Google Scholar 

Schwenger E, Reddy VP, Moorthy G, Sharma P, Tomkinson H, Masson E, Vishwanathan K (2018) Harnessing meta-analysis to refine an oncology patient population for physiology-based pharmacokinetic modeling of drugs. Clin Pharmacol Ther 103(2):271–280. https://doi.org/10.1002/cpt.917

Article  CAS  PubMed  Google Scholar 

Sorich MJ, Mutlib F, van Dyk M, Hopkins AM, Polasek TM, Marshall JC, Rodrigues AD, Rowland A (2019) Use of physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in Axitinib exposure: a fresh approach to precision dosing in oncology. J Clin Pharmacol 59(6):872–879. https://doi.org/10.1002/jcph.1377

Article  CAS  PubMed  Google Scholar 

Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, Wong S, Joshi A, Kenny JR (2013) A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther 94(2):260–268. https://doi.org/10.1038/clpt.2013.79

Article  CAS  PubMed  Google Scholar 

Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H (2016) Development of a physiologically based pharmacokinetic model to predict disease-mediated therapeutic protein-drug interactions: modulation of multiple cytochrome P450 enzymes by interleukin-6. AAPS J 18(3):767–776. https://doi.org/10.1208/s12248-016-9890-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner PK, Hall SD, Chapman SC, Rehmel JL, Royalty JE, Guo Y, Kulanthaivel P (2020) Abemaciclib does not have a clinically meaningful effect on pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 substrates in patients with cancer. Drug Metab Dispos 48(9):796–803. https://doi.org/10.1124/dmd.119.090092

Article  CAS  PubMed  Google Scholar 

Mercan R, Bitik B, Tufan A, Bozbulut UB, Atas N, Ozturk MA, Haznedaroglu S, Goker B (2016) The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and Ankylosing Sspondylitis. J Clin Lab Anal 30(5):597–601. https://doi.org/10.1002/jcla.21908

Article  CAS  PubMed  Google Scholar 

Takada T, Hoogland J, Yano T, Fujii K, Fujiishi R, Miyashita J, Takeshima T, Hayashi M, Azuma T, Moons KGM (2020) Added value of inflammatory markers to vital signs to predict mortality in patients suspected of severe infection. Am J Emerg Med 38(7):1389–1395. https://doi.org/10.1016/j.ajem.2019.11.030

Article  PubMed  Google Scholar 

Babu S, Pulicken M, Thazhathuveedu AK (2022) Peripheral blood neutrophil-to-lymphocyte ratio as a predictor of functional outcomes in patients with hemorrhagic stroke. Indian J Crit Care Med 26(1):18–22. https://doi.org/10.5005/jp-journals-10071-24074

Article  PubMed  PubMed Central  Google Scholar 

Subhani F, Chhotani AA, Waheed S, Zahid RO, Azizi K, Buksh AR (2022) Development of COVID-19 severity assessment score in adults presenting with COVID-19 to the emergency department. BMC Infect Dis 22(1):576. https://doi.org/10.1186/s12879-022-07535-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erre GL, Paliogiannis P, Castagna F, Mangoni AA, Carru C, Passiu G, Zinellu A (2019) Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Invest 49(1):e13037. https://doi.org/10.1111/eci.13037

Article  PubMed  Google Scholar 

Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 47(17):2633–2641. https://doi.org/10.1016/j.ejca.2011.03.028

Article  PubMed  Google Scholar 

Yamamoto T, Kawada K, Obama K (2021) Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci 22(15). https://doi.org/10.3390/ijms22158002

Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S (2011) Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther 89(5):735–740. https://doi.org/10.1038/clpt.2011.35

Article  CAS  PubMed  Google Scholar 

Guo Y, Lucksiri A, Dickinson GL, Vuppalanchi RK, Hilligoss JK, Hall SD (2020) Quantitative prediction of CYP3A4- and CYP3A5-mediated drug interactions. Clin Pharmacol Ther 107(1):246–256. https://doi.org/10.1002/cpt.1596

Article  CAS  PubMed  Google Scholar 

Cheeti S, Budha NR, Rajan S, Dresser MJ, Jin JY (2013) A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos 34(3):141–154. https://doi.org/10.1002/bdd.1830

Article  CAS  PubMed  Google Scholar 

Pilla Reddy V, Walker M, Sharma P, Ballard P, Vishwanathan K (2018) Development, verification, and prediction of osimertinib drug-drug interactions using PBPK modeling approach to inform drug label. CPT Pharmacometrics Syst Pharmacol 7(5):321–330. https://doi.org/10.1002/psp4.12289

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM (2001) Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58(6):1008–1015

Article  CAS  PubMed  Google Scholar 

Iwase S, Murakami T, Saito Y, Nakagawa K (2004) Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw 15(4):312–316

CAS  PubMed  Google Scholar 

Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL (2012) Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 30(13):1527–1533. https://doi.org/10.1200/jco.2011.38.9346

Article  CAS  PubMed  Google Scholar 

Franken LG, Masman AD, de Winter BCM, Baar FPM, Tibboel D, van Gelder T, Koch BCP, Mathot RAA (2017) Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect? Br J Clin Pharmacol 83(8):1701–1712. https://doi.org/10.1111/bcp.13259

Article  CAS  PubMed  PubMed Central